Polyrizon Ltd

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays

[Polyrizon Ltd @Polyrizon_Bio]

https://t.co/G3ExIJNPsA

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Advances Nasarix Study With 3 Major US Trial Sites

https://t.co/kNygoJ8YUg

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

https://t.co/IV73OPKoDs

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

https://t.co/XKaLgUcBy5

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon signs first clinical trial agreement for allergy drug

https://t.co/id2JgQQH2x

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

https://t.co/oxj88afaF6

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

https://t.co/QOF9z0l4Ry

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

https://t.co/kc7EOYJ0sl

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

https://t.co/11CRI5Y4FK

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Launches GMP Manufacturing for U.S. Clinical Trial

https://t.co/2tvlKi6Lg8

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

https://t.co/0xTEkzD9H7

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon reports nasal deposition study results for naloxone

https://t.co/OrOvcpAqu2

@Investingcom $PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Study Finds Enhanced Nasal Deposition Profile for Proprietary Naloxone Formulation

https://t.co/DaTO8d1ebv

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Ltd. Reports Promising Results in Nasal Deposition Study for Naloxone Formulation

https://t.co/L12CR3fJOX

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

https://t.co/KVHTn7TlBE

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon to develop intranasal formulation of Clearmind’s MEAI

https://t.co/wqyJrOtPxz

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon partners with Clearmind to develop intranasal MEAI formulation

https://t.co/tZkx9pkppb

$PLRZ @Street_Insider

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

https://t.co/UQQgCVFtgP

$PLRZ @StockTitan_net

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

https://t.co/S1YMW5oFDe

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

https://t.co/4ZqIk4IUXX

$PLRZ

[Polyrizon Ltd @Polyrizon_Bio]

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

https://t.co/laKdxDLKKg

$PLRZ